# Kisspeptin — Research Peptide Profile

> Triggers up to 50-fold LH surges and acts as the master switch of human puberty. IVF trigger trials with lower OHSS risk, GPR54 mechanism & half-life.

Source: https://peptpedia.org/peptide/kisspeptin | Published: 2025-12-02 | Last updated: 2026-08-04

Kisspeptin is the peptide that switches on human puberty, governing the entire reproductive axis through the GPR54 receptor. Clinical research uses it to trigger egg maturation in IVF with lower hyperstimulation risk than standard triggers. It remains investigational in most countries.

## Overview

Kisspeptin is a neuropeptide family encoded by the KISS1 gene that serves as the essential master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Loss-of-function mutations in KISS1 or its receptor [GPR54 (KISS1R)](/research/kisspeptin-gpr54-gnrh-reproductive-axis) cause complete failure of pubertal onset. Kisspeptin activates GnRH neurons to trigger LH and FSH release driving sex hormone production. Primary research applications include hypothalamic hypogonadism, IVF ovulation triggering as an OHSS-sparing alternative to hCG, infertility evaluation, and [sexual motivation disorders](/peptide/pt-141).

## Molecular Profile

- **Category:** metabolic
- **Molecular formula:** C63H83N17O14
- **Molecular weight:** 1302.44 g/mol
- **CAS number:** 374675-21-5
- **Amino acid sequence:** Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
- **Also known as:** Kisspeptin-10, KP-10, Metastin
- **Half-life:** Short; approximately 28 minutes
- **Solubility:** Soluble in water
- **Storage:** Store at -20°C.

## Mechanism of Action

Kisspeptin acts on GPR54 (KISS1R) receptors on GnRH neurons in the hypothalamus, stimulating the release of gonadotropin-releasing hormone (GnRH). This in turn triggers the release of LH and FSH from the pituitary, which regulate sex hormone production. Kisspeptin serves as the key link between environmental/metabolic signals and reproductive function.

## Key Research Findings

- Kisspeptin is the master switch for human puberty, and loss-of-function mutations in either the KISS1 gene or its GPR54 receptor cause a complete absence of sexual maturation.
- Intravenous kisspeptin produces up to 50 fold increases in luteinizing hormone, making it the most potent known stimulator of the human reproductive hormone axis.
- In IVF clinical trials, kisspeptin triggers final egg maturation with a significantly lower risk of ovarian hyperstimulation syndrome compared to the standard hCG trigger protocol.
- Kisspeptin neurons integrate metabolic signals such as leptin and energy status with reproductive function, explaining why extreme dieting or intense athletic training can suppress fertility.

## Dosing Information (Research Context)

Research studies have used various dosages depending on objectives. Intravenous, subcutaneous, and intranasal routes have been studied. Clinical protocols vary.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Intravenous (clinical) | 1 nmol/kg bolus | Per protocol | Used in research/clinical studies; induces robust LH surge within 30 min |
| Subcutaneous (IVF trigger) | KP-54 at 9.6 nmol/kg | Single dose | IVF oocyte maturation triggering protocol (PMID: 25036713) |

## Researched Effects

- **GnRH/LH Release** (evidence: extensive): Research demonstrates Kisspeptin is the most potent known stimulator of the reproductive hormone axis, with intravenous administration producing robust and dose-dependent increases in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through direct activation of GPR54 (KISS1R) receptors on GnRH neurons. Clinical studies have documented LH increases of 10-50 fold above baseline within 30 minutes of Kisspeptin administration, with effects persisting for 1-2 hours depending on dose and formulation used. The peptide's mechanism involves direct depolarization of GnRH neurons in the hypothalamus, triggering synchronized release of gonadotropin-releasing hormone into the hypophyseal portal circulation for delivery to pituitary gonadotropes. Research has shown Kisspeptin administration can restore LH pulsatility in individuals with hypothalamic amenorrhea and other forms of functional gonadotropin deficiency, demonstrating potential therapeutic applications for reproductive hormone restoration. These potent reproductive hormone stimulation properties have established Kisspeptin as an essential research tool for understanding hypothalamic-pituitary-gonadal axis regulation and investigating novel approaches to fertility treatment and hormonal disorder management.
- **Puberty Regulation** (evidence: extensive): Genetic and clinical research has established Kisspeptin as the essential gatekeeper of puberty onset, with loss-of-function mutations in KISS1 or GPR54 genes causing complete absence of puberty and infertility in both humans and animal models. Studies have documented that Kisspeptin neuron activation in the hypothalamus is required for the pubertal increase in GnRH secretion that initiates sexual maturation, with the timing of puberty closely correlated with developmental changes in Kisspeptin expression levels. Research has shown that premature activation of Kisspeptin signaling can induce precocious puberty, while delayed or absent Kisspeptin expression results in hypogonadotropic hypogonadism, confirming the peptide's critical role as the master regulator of pubertal timing. Clinical applications being investigated include use of Kisspeptin as a diagnostic tool for evaluating hypothalamic function in children with delayed or precocious puberty presentations. These puberty regulation mechanisms have positioned Kisspeptin research at the forefront of pediatric endocrinology, with implications for understanding and treating disorders of pubertal timing and adolescent development.
- **Fertility Research** (evidence: moderate): Clinical studies have demonstrated Kisspeptin's significant potential for fertility treatment applications, with research showing the peptide can induce oocyte maturation and ovulation in women undergoing in vitro fertilization (IVF) protocols as an alternative to human chorionic gonadotropin (hCG). Studies indicate Kisspeptin-triggered ovulation may reduce the risk of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication of conventional fertility treatments, while achieving comparable egg retrieval and pregnancy rates. Research in male fertility has documented that Kisspeptin administration increases testosterone production and may improve sperm parameters in men with hypothalamic causes of infertility. The peptide has been investigated as a treatment for functional hypothalamic amenorrhea, with studies showing restoration of normal menstrual cycling and ovulation in women with stress, exercise, or eating disorder-related reproductive dysfunction. These fertility enhancement properties have generated significant interest in Kisspeptin as a novel therapeutic approach for assisted reproduction research, polycystic ovary syndrome management, and understanding the neuroendocrine basis of reproductive disorders.
- **Metabolic Integration** (evidence: moderate): Research reveals Kisspeptin serves as a critical integrator linking metabolic status with reproductive capability, with Kisspeptin neurons receiving direct input from metabolic signals including leptin, insulin, and nutrient availability markers to regulate fertility according to energy balance. Studies have demonstrated that caloric restriction and negative energy balance suppress Kisspeptin expression, providing a mechanistic explanation for the reproductive dysfunction seen in conditions like anorexia nervosa and intense athletic training. The peptide's expression is directly regulated by leptin signaling, explaining why leptin deficiency causes infertility and why leptin treatment can restore reproductive function in some metabolic conditions. Research indicates Kisspeptin neurons also modulate feeding behavior and energy expenditure, suggesting bidirectional communication between reproductive and metabolic control systems in the hypothalamus. These metabolic-reproductive integration properties have important implications for understanding infertility associated with obesity, diabetes, and metabolic syndrome, as well as developing interventions to restore fertility in metabolically compromised individuals.
- **Sexual Behavior Effects** (evidence: preliminary): Emerging research indicates Kisspeptin may influence sexual behavior and arousal through actions beyond its reproductive hormone effects, with studies demonstrating the peptide modulates brain regions involved in sexual motivation and attraction. Clinical studies have shown Kisspeptin administration enhances brain responses to sexual images in functional MRI studies, with increased activation in limbic structures including the amygdala and cingulate cortex associated with emotional processing and reward. Research suggests Kisspeptin may enhance sexual arousal and desire through direct effects on brain circuits independent of its downstream effects on sex hormones, potentially offering therapeutic applications for sexual dysfunction. The peptide appears to enhance psychological aspects of sexual attraction and may improve partner bonding behaviors in addition to physical reproductive processes. These sexual behavior research findings have expanded understanding of Kisspeptin's role beyond simple gonadotropin regulation and opened new research directions in psychosexual medicine and treatment of desire disorders.

## Research Applications

- Reproductive Endocrinology
- Fertility Research
- Puberty Studies
- Neuroendocrinology
- Metabolic Research
- Sexual Medicine

## Key Studies

### Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males

Dhillo WS, et al. — *Journal of Clinical Endocrinology and Metabolism* (2005) — [PMID 16174713](https://pubmed.ncbi.nlm.nih.gov/16174713/) | [doi:10.1210/jc.2005-1468](https://doi.org/10.1210/jc.2005-1468)

This pioneering clinical study demonstrated that kisspeptin stimulates the human hypothalamic-pituitary-gonadal axis, establishing its role in regulating reproductive hormone release. In a double-blind, placebo-controlled, crossover design, six male volunteers each received a single 90-minute intravenous infusion of Kisspeptin-54 (4 pmol/kg per minute) and a saline control infusion in random order. Compared with saline, kisspeptin infusion significantly increased plasma luteinizing hormone (mean 90-minute LH, 10.8 vs. 4.2 U/liter), follicle-stimulating hormone (FSH, 3.9 vs. 3.2 U/liter), and testosterone (mean 180-minute, 24.9 vs. 21.7 nmol/liter), all statistically significant. The plasma half-life of kisspeptin-54 was calculated to be approximately 28 minutes. These findings established that elevating circulating kisspeptin significantly raises LH, FSH, and testosterone in human males, providing a novel mechanism for manipulating the hypothalamic-pituitary-gonadal axis in disorders of the reproductive system.

### Kisspeptin modulates sexual and emotional brain processing in humans

Comninos AN, Wall MB, et al. — *Journal of Clinical Investigation* (2017) — [PMID 28112678](https://pubmed.ncbi.nlm.nih.gov/28112678/) | [doi:10.1172/JCI89519](https://doi.org/10.1172/JCI89519)

This innovative neuroimaging study investigated Kisspeptin's effects on brain activity related to sexual arousal, emotional processing, and mood in healthy volunteers using functional MRI techniques. Researchers administered Kisspeptin and measured brain responses to visual stimuli including sexual images, romantic scenes, and emotional content, documenting enhanced activation in limbic structures involved in reward and emotional processing. The study revealed that Kisspeptin specifically increased activity in the amygdala, cingulate cortex, and other brain regions associated with sexual attraction and romantic bonding, independent of changes in peripheral sex hormones. Analysis showed the peptide also enhanced positive mood measures and reduced negative emotional processing, suggesting broader effects on psychological wellbeing beyond reproductive function. These findings expanded understanding of Kisspeptin beyond simple gonadotropin regulation and identified potential applications in treating psychosexual disorders and depression associated with hypogonadism.

### Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization

Jayasena CN, Abbara A, et al. — *Journal of Clinical Investigation* (2014) — [PMID 25036713](https://pubmed.ncbi.nlm.nih.gov/25036713/) | [doi:10.1172/JCI75730](https://doi.org/10.1172/JCI75730)

This clinical study evaluated Kisspeptin-54 as a trigger for final egg maturation in women undergoing in vitro fertilization (IVF). Following superovulation with recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women were given a single subcutaneous injection of Kisspeptin-54 across a range of doses (1.6 to 12.8 nmol/kg) to induce a luteinizing hormone surge and egg maturation. Eggs were retrieved transvaginally 36 hours after injection and fertilized by intracytoplasmic sperm injection, with subsequent transfer of one or two embryos. Egg maturation was observed at every tested dose, and the mean number of mature eggs per patient generally increased in a dose-dependent manner. Fertilization of eggs and transfer of embryos to the uterus occurred in 92% (49/53) of Kisspeptin-54-treated patients, with biochemical and clinical pregnancy rates of 40% (21/53) and 23% (12/53), respectively. These findings demonstrated that a single injection of Kisspeptin-54 can induce egg maturation leading to successful human pregnancy, establishing it as a candidate trigger for IVF.

## Frequently Asked Questions

### Why is Kisspeptin important for reproduction?

Kisspeptin is the master switch for human reproduction at the hypothalamic level. Loss-of-function mutations in the KISS1 gene or the GPR54/KISS1R receptor cause a complete failure of puberty (idiopathic hypogonadotropic hypogonadism) and sterility. Kisspeptin neurons in the arcuate nucleus generate the 'pulse generator' that drives episodic GnRH release throughout adult reproductive life. Crucially, these kisspeptin neurons integrate metabolic signals (leptin, insulin), stress signals (cortisol, CRH), and photoperiod cues to regulate when reproduction is appropriate—explaining why extreme dieting, excessive exercise, or severe stress can suppress the reproductive axis.

### What are the clinical applications of Kisspeptin?

Current clinical and near-clinical applications include: (1) IVF triggering—Kisspeptin-54 (9.6 nmol/kg SC) achieves 91% oocyte maturation with reduced OHSS risk in high-risk IVF patients (PMID: 26030227); (2) Diagnostic testing for hypogonadotropic hypogonadism—Kisspeptin stimulation tests can differentiate hypothalamic from pituitary failure; (3) Hypothalamic amenorrhea treatment—IV Kisspeptin pulsatile infusion has restored LH pulsatility in women with exercise- or diet-induced amenorrhea in clinical studies; (4) Hypogonadotropic hypogonadism treatment—ongoing trials exploring Kisspeptin analog development for inducing puberty or restoring gonadal function.

### How does Kisspeptin regulate LH pulsatility?

LH is secreted in pulses (approximately every 90–120 minutes in normally cycling adults) rather than continuously. This pulsatility is essential—continuous GnRH/LH stimulation actually causes receptor downregulation and gonadal suppression (the basis of GnRH agonist treatments for endometriosis and prostate cancer). Kisspeptin neurons in the arcuate nucleus generate the pulse timing—they exhibit 'synchronized burst firing' that drives coordinated GnRH pulses. The frequency and amplitude of Kisspeptin firing is modulated by estradiol feedback. Kisspeptin analogs with extended half-life are being developed, but need careful dosing to maintain pulsatility rather than creating continuous stimulation.

### What is the connection between Kisspeptin and sexual attraction?

fMRI studies by Dhillo et al. at Imperial College London found that intravenous Kisspeptin administration in healthy men enhanced brain activation in limbic regions (amygdala, cingulate cortex) in response to sexual images, while simultaneously increasing positive emotional responses to non-sexual stimuli and decreasing negative emotional responses. This occurred without changes in testosterone levels, suggesting Kisspeptin has direct central effects on sexual behavior and mood independent of its gonadotropin-stimulating action. These findings suggest Kisspeptin neurons are involved in the integration of sexual motivation and mood—not just hormone secretion control.

### How does body weight and nutrition affect Kisspeptin?

Kisspeptin neurons directly receive inputs from leptin receptors (the adiposity signal). Adequate leptin levels are required for normal Kisspeptin neuron activity—leptin deficiency (from starvation or extreme weight loss) dramatically reduces Kisspeptin expression in the arcuate nucleus, suppressing GnRH pulses and causing anovulation (missed periods) or impotence. This is the mechanistic explanation for why athletes in energy deficit (Relative Energy Deficiency in Sport, RED-S), anorexic patients, and extremely lean individuals have suppressed reproductive function. Restoring energy balance increases leptin, restoring Kisspeptin signaling and reproductive function.

### What is Kisspeptin's role in IVF and ovulation induction?

Kisspeptin-54 has been evaluated as a 'trigger shot' alternative in IVF—replacing the hCG injection used to trigger final oocyte maturation before egg retrieval. The critical advantage: Kisspeptin triggers LH surge via the hypothalamus-pituitary axis, producing a natural, self-limited LH pulse rather than the sustained pharmacological hCG stimulation that causes ovarian hyperstimulation syndrome (OHSS). A landmark study (PMID: 26192876; Abbara et al., J Clin Endocrinol Metab 2015) demonstrated Kisspeptin-54 achieved 91% oocyte maturation in high-OHSS-risk patients with zero clinical OHSS cases—compared to historically 5–10% severe OHSS rates with hCG triggers. This represents the most clinically validated application of Kisspeptin in 2026.

### What are the different forms of Kisspeptin and how do they differ?

The KISS1 gene encodes a 145-amino-acid precursor (metastin) that is cleaved into multiple C-terminally amidated forms: Kisspeptin-54, Kisspeptin-14, Kisspeptin-13, and Kisspeptin-10. All share the same C-terminal decapeptide (Kisspeptin-10) which is the minimal sequence for GPR54 receptor activation. Kisspeptin-54 is the predominant circulating form in humans, while Kisspeptin-10 is the shortest fully active fragment. Kisspeptin-10 has a shorter half-life (~3 min IV) than Kisspeptin-54 (~26 min IV) due to less protection from amino-terminal processing. For pulsatile GnRH stimulation research, Kisspeptin-10 is used in IV infusion protocols; for IVF triggering, Kisspeptin-54 is preferred for its longer duration.

### How does Kisspeptin research inform understanding of puberty disorders?

Loss-of-function mutations in KISS1 or KISS1R (GPR54) cause hypogonadotropic hypogonadism (HH)—complete failure of puberty onset with absent GnRH pulses, low LH/FSH, and absent sex steroid production. This phenotype was a major discovery in reproductive neuroendocrinology because it identified Kisspeptin as non-redundant and essential for pubertal onset. Conversely, activating KISS1R mutations cause central precocious puberty. These natural human genetic experiments powerfully validate Kisspeptin's physiological necessity. From a therapeutic standpoint, Kisspeptin analog development for treating HH is ongoing—pulsatile Kisspeptin IV infusion has successfully induced LH pulsatility and testosterone/estradiol production in HH patients in research studies.

## Related Peptides

- [PT-141](https://peptpedia.org/peptide/pt-141)
- [Oxytocin](https://peptpedia.org/peptide/oxytocin)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org